Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04715568 · ClinicalTrials.gov registry record · Phase 4
Secondhand Tobacco Smoke and Cardiovascular Disease
A Phase 4 study of Hypertension and Cardiovascular Diseases, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04715568 is a Phase 4 study of Hypertension and Cardiovascular Diseases that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 100 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04715568, a Phase 4 study of Hypertension and Cardiovascular Diseases, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Losartan
Study Locations (1)
California
- San Francisco Veterans' Affairs Medical Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04715568
The ClinicalTrials.gov registry entry for NCT04715568 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04715568 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04715568 about?
NCT04715568 is a clinical study titled "Secondhand Tobacco Smoke and Cardiovascular Disease". This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to second...
What is the current status of trial NCT04715568?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2021-03-30. Estimated completion is 2026-12-31.
What conditions does trial NCT04715568 study?
This clinical trial studies the following conditions: Hypertension, Cardiovascular Diseases.
What interventions are being tested in trial NCT04715568?
The interventions under investigation include: Placebo (DRUG), Losartan (DRUG).
Who is sponsoring clinical trial NCT04715568?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04715568 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
MR Antagonist and LSD1
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.